Business description: Amgen Inc.

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:

- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;

- other (5.8%): primarily royalties.

The United States account for 70.3% of net sales.

Number of employees: 26,700

Sales by Activity: Amgen Inc.

Fiscal Period: December20192020202120222023

Human Therapeutics

23.36B 25.42B 25.98B 26.32B 28.19B
See all business segments

Geographical breakdown of sales: Amgen Inc.

Fiscal Period: December20192020202120222023

United States (U.S.)

17.22B 18.5B 18.19B 18.6B 19.81B

Rest of The World (Row)

6.14B 6.93B 7.78B 7.73B 8.38B
See all geographic segments

Managers: Amgen Inc.

Director TitleAgeSince
Chief Executive Officer 62 2012-04-30
Director of Finance/CFO 66 2019-12-31
Chief Tech/Sci/R&D Officer 62 2018-07-25
Chief Operating Officer 57 2016-07-24
Chief Tech/Sci/R&D Officer - 2024-12-15
See AMGEN INC. governance

Members of the board: Amgen Inc.

Manager TitleAgeSince
Chairman 62 2012-12-31
Director/Board Member 64 2011-12-31
Director/Board Member 70 2002-12-31
Director/Board Member 67 2013-10-15
Director/Board Member 69 2016-10-13
Director/Board Member 68 2017-02-02
Director/Board Member 70 2017-10-23
Director/Board Member 69 2018-05-22
Director/Board Member 58 2020-07-22
Director/Board Member 69 2021-07-29
Composition of the Board of Directors

Shareholders: Amgen Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.745 %
52,382,273 9.745 % 14 951 M $
BlackRock Advisors LLC
6.342 %
34,092,697 6.342 % 9 731 M $
29,317,018 5.454 % 8 368 M $
Eaton Vance Management
2.734 %
14,694,221 2.734 % 4 194 M $
Charles Schwab Investment Management, Inc.
2.457 %
13,205,604 2.457 % 3 769 M $
NameEquities%Valuation
BRAM - Bradesco Asset Management SA DTVM
0.000211 %
31,704 0.000211 % 324 557 $
Safra Asset Management Ltda.
0.000146 %
22,000 0.000146 % 225 216 $
List of AMGEN INC. shareholders

Holdings: Amgen Inc.

NameEquities%Valuation
246,269,42619.39%4,368,597,975 $
35,368,65321.89%68,261,500 $
3,206,2817.84%7,630,949 $

Company details: Amgen Inc.

Amgen, Inc.

One Amgen Center Drive

91320-1799, Thousand Oaks

+805 447 1000

http://www.amgen.com
address Amgen Inc.(AMGN)

Group companies: Amgen Inc.

NameCategory and Sector
Amgen Manufacturing Ltd. (Bermuda)
Biotechnology
Pharmaceuticals: Major
Miscellaneous
See all subsidiaries

Other Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-0.14%+1.47%-0.40%+28.51% 158B
-0.13%+4.84%+17.47%+267.39% 782B
-2.47%+1.28%-27.74%+83.27% 378B
+1.23%+1.76%-1.05%-6.87% 371B
+0.31%+0.35%+10.13%+34.22% 336B
-0.83%+0.77%+26.68%-17.36% 256B
-0.80%+5.39%+22.35%+36.59% 225B
+1.13%+2.56%+11.82%+22.90% 210B
-1.18%-1.11%-7.51%-49.62% 147B
-0.15%+0.93%+20.41%+10.46% 134B
Average -0.29%+1.97%+7.22%+40.95% 299.79B
Weighted average by Cap. -0.27%+3.25%+7.38%+85.68%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
294.79USD
Average target price
316.70USD
Spread / Average Target
+7.43%
Consensus

Quarterly revenue - Rate of surprise